塔斯马尼亚::75 0872::塔斯马特 (11-8470187)-猫眼课题宝

塔斯马尼亚::75 0872::塔斯马特 (11-8470187)

批准号：

8602367

负责人：

HANNA NG

金额：

$185.94万

依托单位：

SRI INTERNATIONAL

依托单位国家：

美国

项目类别：

财政年份：

2010

资助国家：

美国

项目状态：

已结题

起止时间：

2010-11-08 至 2015-11-07

来源：

https://reporter.nih.gov/project-details/8602367

关键词：

Accreditation Animals Basic Science Biodistribution Canis familiaris Client Clinic Clinical Clinical Research Communities Consult Contractor Contracts Data Development Government Guidelines Heart Diseases Hematological Disease Human Individual International Knowledge Lung diseases National Heart, Lung, and Blood Institute Oryctolagus cuniculus Performance Pharmaceutical Preparations Pharmacology Pharmacology and Toxicology Phase Preclinical Testing Qualifying Regulation Reporting Request for Proposals Research Research Design Research Institute Research Personnel Resources Rodent Safety Science Scientist Services System Testing Therapeutic Therapeutic Intervention Toxicology Translational Research Translations Treatment Protocols United States National Institutes of Health Work animal care case-by-case basis cost effective design drug candidate drug development experience flexibility good laboratory practice in vitro Assay interest meetings nonhuman primate novel pre-clinical preclinical study programs response small molecule symposium

项目摘要

项目成果

HANNA NG的其他基金

相似基金

相关文献

中文摘要

翻译

为响应招标书（RFP），NHLBI-HV-1 0-11，SRI International（SRI，前身为斯坦福大学研究研究所）提议作为药理学和毒理学研究所的一个灵活和响应迅速的资源承包商，中心（PTC），以支持科学转向艺术研究翻译和治疗（SMARTT）计划的国家心脏、肺和血液研究所（NHLBI）SMARTT计划的目的是提供资源，如咨询、制造、药理学和毒理学测试、临床前和早期临床研究设计支持，以及管理和监管专业知识，以协助将新的合成，自然的，或生物治疗干预出现在科学界的治疗心脏，肺，血液病。

英文摘要

In response to Request of Proposal (RFP), NHLBI-HV-1 0-11, SRI International (SRI, formerly Stanford Research Institute) proposes to act as a flexible and responsive resource contractor as the Pharmacology and Toxicology Center (PTC) to support the Science Moving towArds Research Translation and Therapy (SMARTT) program of the National Heart, Lung, and Blood Institute (NHLBI). The purpose of the SMARTT program is to provide resources, such as consulting, manufacturing, pharmacology and toxicology testing, preclinical and early-phase clinical study design support, and administrative and regulatory expertise, to assist translation to the clinic of novel synthetic, natural, or biologic therapeutic interventions arising in the scientific community for the treatment of heart, lung, and blood diseases.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文